Skip to main content
Erschienen in: Annals of Hematology 1/2018

18.10.2017 | Review Article

Transformed follicular lymphoma

verfasst von: Thais Fischer, Natalia Pin Chuen Zing, Carlos Sergio Chiattone, Massimo Federico, Stefano Luminari

Erschienen in: Annals of Hematology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Follicular Lymphoma (FL) is the second most common type of non-Hodgkin lymphoma and is considered to be the prototype of indolent lymphomas. Histologic transformation into an aggressive lymphoma, which is expected to occur at a rate of 2 to 3% each year, is associated with rapid progression, treatment resistance, and poor prognosis. Recent modifications to the physiopathologic mechanism of transformed follicular lymphoma (t-FL) have been proposed, including genetic and epigenetic mechanisms as well as a role for the microenvironment. Although t-FL is considered a devastating complication, as it is associated with treatment-refractory disease and a dismal outcome, recent data in the rituximab era have suggested that not only is the prognosis less severe than reported in the previous literature but the risk of transformation is also lower. Thus, this study aimed to review the most recent research on t-FL in an attempt to better understand the clinical meaning of transformation from FL to diffuse large B cell lymphoma (DLBCL) and the impact of current treatment strategies on the curability of this intriguing subentity of lymphoma.
Literatur
1.
Zurück zum Zitat Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84(5):1361–1392PubMed Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84(5):1361–1392PubMed
2.
Zurück zum Zitat Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17(12):3835–3849. https://doi.org/10.1200/JCO.1999.17.12.3835 PubMedCrossRef Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17(12):3835–3849. https://​doi.​org/​10.​1200/​JCO.​1999.​17.​12.​3835 PubMedCrossRef
4.
Zurück zum Zitat Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N et al (2011) Non-Hodgkin’s lymphomas. J Natl Compr Cancer Netw 9(5):484–560CrossRef Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N et al (2011) Non-Hodgkin’s lymphomas. J Natl Compr Cancer Netw 9(5):484–560CrossRef
12.
Zurück zum Zitat Lambrechts AC, Hupkes PE, Dorssers LC, van't Veer MB (1993) Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non-Hodgkin's lymphoma. Blood 82(8):2510–2516PubMed Lambrechts AC, Hupkes PE, Dorssers LC, van't Veer MB (1993) Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non-Hodgkin's lymphoma. Blood 82(8):2510–2516PubMed
16.
Zurück zum Zitat Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210. https://doi.org/10.1016/S0140-6736(12)61763-2 PubMedCrossRef Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210. https://​doi.​org/​10.​1016/​S0140-6736(12)61763-2 PubMedCrossRef
20.
Zurück zum Zitat Lossos IS, Levy R (2003) Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol 13(3):191–202PubMedCrossRef Lossos IS, Levy R (2003) Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol 13(3):191–202PubMedCrossRef
23.
25.
Zurück zum Zitat Cullen MH, Lister TA, Brearley RI, Shand WS, Stansfeld AG (1979) Histological transformation of non-Hodgkin's lymphoma: a prospective study. Cancer 44(2):645–651PubMedCrossRef Cullen MH, Lister TA, Brearley RI, Shand WS, Stansfeld AG (1979) Histological transformation of non-Hodgkin's lymphoma: a prospective study. Cancer 44(2):645–651PubMedCrossRef
28.
29.
Zurück zum Zitat Gall EA, Mallory TB (1942) Malignant lymphoma: a clinico-pathologic survey of 618 cases. Am J Pathol 18(3):381–429PubMedPubMedCentral Gall EA, Mallory TB (1942) Malignant lymphoma: a clinico-pathologic survey of 618 cases. Am J Pathol 18(3):381–429PubMedPubMedCentral
31.
37.
Zurück zum Zitat Yasukawa M, Bando S, Dolken G, Sada E, Yakushijin Y, Fujita S et al (2001) Low frequency of BCL-2/J(H) translocation in peripheral blood lymphocytes of healthy Japanese individuals. Blood 98(2):486–488PubMedCrossRef Yasukawa M, Bando S, Dolken G, Sada E, Yakushijin Y, Fujita S et al (2001) Low frequency of BCL-2/J(H) translocation in peripheral blood lymphocytes of healthy Japanese individuals. Blood 98(2):486–488PubMedCrossRef
43.
Zurück zum Zitat Yano T, Jaffe ES, Longo DL, Raffeld MMYC (1992) Rearrangements in histologically progressed follicular lymphomas. Blood 80(3):758–767PubMed Yano T, Jaffe ES, Longo DL, Raffeld MMYC (1992) Rearrangements in histologically progressed follicular lymphomas. Blood 80(3):758–767PubMed
47.
Zurück zum Zitat Smit LA, Bende RJ, Aten J, Guikema JE, Aarts WM, van Noesel CJ (2003) Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. Cancer Res 63(14):3894–3898PubMed Smit LA, Bende RJ, Aten J, Guikema JE, Aarts WM, van Noesel CJ (2003) Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. Cancer Res 63(14):3894–3898PubMed
54.
Zurück zum Zitat Yuen AR, Kamel OW, Halpern J, Horning SJ (1995) Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 13(7):1726–1733PubMedCrossRef Yuen AR, Kamel OW, Halpern J, Horning SJ (1995) Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 13(7):1726–1733PubMedCrossRef
56.
Zurück zum Zitat Natkunam Y, Soslow R, Matolcsy A, Dolezal M, Bhargava V, Knowles DM et al (2004) Immunophenotypic and genotypic characterization of progression in follicular lymphomas. Appl Immunohistochem Mol Morphol 12(2):97–104PubMedCrossRef Natkunam Y, Soslow R, Matolcsy A, Dolezal M, Bhargava V, Knowles DM et al (2004) Immunophenotypic and genotypic characterization of progression in follicular lymphomas. Appl Immunohistochem Mol Morphol 12(2):97–104PubMedCrossRef
61.
62.
Zurück zum Zitat Gollub W, Stassek B, Huckhagel T, Bernd HW, Krokowski M, Merz H et al (2009) BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2. Anticancer Res 29(11):4649–4655PubMed Gollub W, Stassek B, Huckhagel T, Bernd HW, Krokowski M, Merz H et al (2009) BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2. Anticancer Res 29(11):4649–4655PubMed
67.
Zurück zum Zitat Luminari S, Biasoli I, Arcaini L, Versari A, Rusconi C, Merli F et al (2013) The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 24(8):2108–2112. https://doi.org/10.1093/annonc/mdt137 PubMedCrossRef Luminari S, Biasoli I, Arcaini L, Versari A, Rusconi C, Merli F et al (2013) The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 24(8):2108–2112. https://​doi.​org/​10.​1093/​annonc/​mdt137 PubMedCrossRef
71.
Zurück zum Zitat Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Zelenetz AD et al (2017) [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma 58(4):809–815. https://doi.org/10.1080/10428194.2016.1213824 PubMedCrossRef Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Zelenetz AD et al (2017) [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma 58(4):809–815. https://​doi.​org/​10.​1080/​10428194.​2016.​1213824 PubMedCrossRef
76.
Zurück zum Zitat Gine E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N et al (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17(10):1539–1545. https://doi.org/10.1093/annonc/mdl162 PubMedCrossRef Gine E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N et al (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17(10):1539–1545. https://​doi.​org/​10.​1093/​annonc/​mdl162 PubMedCrossRef
79.
Zurück zum Zitat Federico M CD, Marcheselli L, Tarantino V, Sarkozy C, Lopez Guillermo A, Wondergem M, Kimby E, Rusconi C,. Zucca E, Montoto S, da Silva MG, Aurer I, Paszkiewicz-Kozik E, Cartron G, Morschhauser F, Alcoceba M, Chamuleau M, Lockmer S, Minoia C, Issa D, Alonso S, Conte L, Salles G, Coiffier B (2017) The risk of transformation offollicular lymphoma“transformed” by rituximab: the Aristotle study promoted by the European Lymphoma Institute. Hematol Oncol 35, issue supplement S2(June 2017): 115-116. e-pub ahead of print http://onlinelibrary.wiley.com/doi/10.1002/hon.2437_104/e.pdf; Federico M CD, Marcheselli L, Tarantino V, Sarkozy C, Lopez Guillermo A, Wondergem M, Kimby E, Rusconi C,. Zucca E, Montoto S, da Silva MG, Aurer I, Paszkiewicz-Kozik E, Cartron G, Morschhauser F, Alcoceba M, Chamuleau M, Lockmer S, Minoia C, Issa D, Alonso S, Conte L, Salles G, Coiffier B (2017) The risk of transformation offollicular lymphoma“transformed” by rituximab: the Aristotle study promoted by the European Lymphoma Institute. Hematol Oncol 35, issue supplement S2(June 2017): 115-116. e-pub ahead of print http://​onlinelibrary.​wiley.​com/​doi/​10.​1002/​hon.​2437_​104/​e.​pdf;
81.
Zurück zum Zitat Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, Press OW et al (2010) Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol 21(6):1196–1202. https://doi.org/10.1093/annonc/mdp460 PubMedCrossRef Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, Press OW et al (2010) Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol 21(6):1196–1202. https://​doi.​org/​10.​1093/​annonc/​mdp460 PubMedCrossRef
84.
Zurück zum Zitat Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin A et al (1994) Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84(4):1043–1049PubMed Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin A et al (1994) Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84(4):1043–1049PubMed
86.
Zurück zum Zitat Lossos IS, Levy R (2000) Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5′ noncoding regulatory region of the BCL-6 gene. Blood 96(2):635–639PubMed Lossos IS, Levy R (2000) Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5′ noncoding regulatory region of the BCL-6 gene. Blood 96(2):635–639PubMed
87.
Zurück zum Zitat Matolcsy A, Casali P, Warnke RA, Knowles DM (1996) Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 88(10):3937–3944PubMed Matolcsy A, Casali P, Warnke RA, Knowles DM (1996) Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 88(10):3937–3944PubMed
89.
Zurück zum Zitat Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES et al (1993) p53 mutation is associated with progression in follicular lymphomas. Blood 82(7):1994–2004PubMed Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES et al (1993) p53 mutation is associated with progression in follicular lymphomas. Blood 82(7):1994–2004PubMed
90.
Zurück zum Zitat Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M (1998) Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91(12):4677–4685PubMed Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M (1998) Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91(12):4677–4685PubMed
91.
Zurück zum Zitat Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M et al (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16(9):1111–1122. https://doi.org/10.1016/S1470-2045(15)00169-2 PubMedCrossRef Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M et al (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16(9):1111–1122. https://​doi.​org/​10.​1016/​S1470-2045(15)00169-2 PubMedCrossRef
95.
Zurück zum Zitat Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B et al (2001) High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19(3):727–735. https://doi.org/10.1200/JCO.2001.19.3.727 PubMedCrossRef Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B et al (2001) High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19(3):727–735. https://​doi.​org/​10.​1200/​JCO.​2001.​19.​3.​727 PubMedCrossRef
98.
Zurück zum Zitat Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F et al (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84(4):1050–1055PubMed Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F et al (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84(4):1050–1055PubMed
102.
Zurück zum Zitat Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P et al (2014) De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol 32(4):282–287. https://doi.org/10.1200/JCO.2013.49.7586 PubMedCrossRef Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P et al (2014) De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol 32(4):282–287. https://​doi.​org/​10.​1200/​JCO.​2013.​49.​7586 PubMedCrossRef
Metadaten
Titel
Transformed follicular lymphoma
verfasst von
Thais Fischer
Natalia Pin Chuen Zing
Carlos Sergio Chiattone
Massimo Federico
Stefano Luminari
Publikationsdatum
18.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 1/2018
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3151-2

Weitere Artikel der Ausgabe 1/2018

Annals of Hematology 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.